EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Recent Advances in 64Cu/67Cu-Based Radiopharmaceuticals

Olga O Krasnovskaya iD, Daniil Abramchuck, Alexander Erofeev, Peter Gorelkin iD, Alexander Kuznetsov, Andrey Shemukhin, Elena K Beloglazkina iD

International Journal of Molecular Sciences · 23.05.2023 · 24 (11) · 9154

DOI: 10.3390/ijms24119154 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 23.05.2023. Verfasst von Olga O Krasnovskaya und 6 weiteren Autor:innen. Beteiligte Einrichtung: Chemistry Department, Lomonosov Moscow State University, Leninskie Gory, 1/3, 119991 Moscow, Russia. Hauptthemen laut MEDLINE: Radiopharmaceuticals, Neoplasms. Die Arbeit wurde bisher 90-mal zitiert (Crossref) und nennt 151 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Russian Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Copper-64 (T1/2 = 12.7 h) is a positron and beta-emitting isotope, with decay characteristics suitable for both positron emission tomography (PET) imaging and radiotherapy of cancer. Copper-67 (T1/2 = 61.8 h) is a beta and gamma emitter, appropriate for radiotherapy β-energy and with a half-life suitable for single-photon emission computed tomography (SPECT) imaging. The chemical identities of 64Cu and 67Cu isotopes allow for convenient use of the same chelating molecules for sequential PET imaging and radiotherapy. A recent breakthrough in 67Cu production opened previously unavailable opportunities for a reliable source of 67Cu with high specific activity and purity. These new opportunities have reignited interest in the use of copper-containing radiopharmaceuticals for the therapy, diagnosis, and theranostics of various diseases. Herein, we summarize recent (2018–2023) advances in the use of copper-based radiopharmaceuticals for PET, SPECT imaging, radiotherapy, and radioimmunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RadiopharmaceuticalsNeoplasmsHumansCopperPositron-Emission TomographyTomography, Emission-Computed, Single-Photon

Stichwörter der Autor:innen

PETSPECTcopper-64copper-67radioimmunotherapyradiotherapy

Substanzen

RadiopharmaceuticalsCopper

Autor:innen und Institutionen

  • Chemistry Department, Lomonosov Moscow State University, Leninskie Gory, 1/3, 119991 Moscow, Russia.
  • Research Laboratory of Biophysics, National University of Science and Technology (MISIS), Leninskiy Prospect 4, 119049 Moscow, Russia.
  • Skobeltsyn Institute of Nuclear Physics, Lomonosov Moscow State University, Leninskie Gory, 1, Bld. 2, 119991 Moscow, Russia.
  • Department of Physics, Lomonosov Moscow State University, Leninskie Gory, 1/2, 119991 Moscow, Russia.

ORCID-Profile: Olga O Krasnovskaya, Peter Gorelkin, Elena K Beloglazkina

Förderung

  • Russian Science Foundation

Zitieren

APA

Krasnovskaya, O. O., Abramchuck, D., Erofeev, A., Gorelkin, P., Kuznetsov, A., Shemukhin, A., & Beloglazkina, E. K. (2023). Recent Advances in 64Cu/67Cu-Based Radiopharmaceuticals. International Journal of Molecular Sciences, 24(11), 9154. https://doi.org/10.3390/ijms24119154

Vancouver

Krasnovskaya OO, Abramchuck D, Erofeev A, Gorelkin P, Kuznetsov A, Shemukhin A, et al. Recent Advances in 64Cu/67Cu-Based Radiopharmaceuticals. International Journal of Molecular Sciences. 2023;24(11):9154. doi:10.3390/ijms24119154

BibTeX
@article{Krasnovskaya2023,
  author = {Krasnovskaya, Olga O and Abramchuck, Daniil and Erofeev, Alexander and Gorelkin, Peter and Kuznetsov, Alexander and Shemukhin, Andrey and Beloglazkina, Elena K},
  title = {Recent Advances in 64Cu/67Cu-Based Radiopharmaceuticals},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {11},
  pages = {9154},
  doi = {10.3390/ijms24119154}
}
Kostenlos starten →